Stock XINT XINTELA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Xintela AB

Equities

XINT

SE0007756903

Biotechnology & Medical Research

Delayed Nasdaq Stockholm
Other stock markets
 10:32:03 2024-04-26 am EDT 		5-day change 1st Jan Change
0.281 SEK +2.55% Intraday chart for Xintela AB +6.04% +3.69%
Feb. 28 Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Feb. 20 Xintela Names New Chief Scientific Officer MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 231.4 164.2 199.7 204.1 150.6 147.9
Enterprise Value (EV) 1 200 163.8 177 193 142.2 140.1
P/E ratio -7.24 x -3.77 x -3.35 x -3.19 x -1.33 x -2.1 x
Yield - - - - - -
Capitalization / Revenue 142 x 4,321 x - - - 1,897 x
EV / Revenue 123 x 4,310 x - - - 1,797 x
EV / EBITDA -9.05 x -4.83 x -5.84 x -3.41 x -2.19 x -2.62 x
EV / FCF -5.98 x -8.98 x -9.36 x -7.87 x -2.74 x -3.93 x
FCF Yield -16.7% -11.1% -10.7% -12.7% -36.5% -25.4%
Price to Book 5.25 x 17.6 x 9.3 x 81.5 x 26.1 x 35.1 x
Nbr of stocks (in thousands) 38,688 39,471 57,543 89,134 307,573 545,909
Reference price 2 5.980 4.160 3.470 2.290 0.4895 0.2710
Announcement Date 5/6/19 5/26/20 4/16/21 4/28/23 4/28/23 4/17/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1.628 0.038 - - - 0.078
EBITDA 1 -22.1 -33.92 -30.33 -56.57 -64.83 -53.47
EBIT 1 -24.2 -38.05 -33.9 -60.07 -69.06 -57.24
Operating Margin -1,486.73% -100,121.05% - - - -73,380.77%
Earnings before Tax (EBT) 1 -26.27 -43.53 -50.26 -60.6 -73.16 -58.37
Net income 1 -26.27 -43.53 -50.26 -59.55 -66.22 -54.08
Net margin -1,613.88% -114,552.63% - - - -69,337.18%
EPS 2 -0.8257 -1.103 -1.035 -0.7186 -0.3685 -0.1288
Free Cash Flow 1 -33.41 -18.24 -18.9 -24.52 -51.94 -35.62
FCF margin -2,052.41% -47,997.37% - - - -45,668.59%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/6/19 5/26/20 4/16/21 4/28/23 4/28/23 4/17/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 31.4 0.41 22.7 11.1 8.34 7.81
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -33.4 -18.2 -18.9 -24.5 -51.9 -35.6
ROE (net income / shareholders' equity) -82.9% -160% -272% -396% -1,599% -1,065%
ROA (Net income/ Total Assets) -38.6% -71.2% -64.6% -99.5% -168% -167%
Assets 1 68 61.15 77.82 59.86 39.48 32.44
Book Value Per Share 2 1.140 0.2400 0.3700 0.0300 0.0200 0.0100
Cash Flow per Share 2 0.8000 0.0100 0.4500 0.1200 0.0300 0.0100
Capex 1 12.2 1.62 0.38 2.43 - 0.1
Capex / Sales 752.21% 4,260.53% - - - 133.33%
Announcement Date 5/6/19 5/26/20 4/16/21 4/28/23 4/28/23 4/17/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
XINTELA AB Stock Xintela AB
+3.69% 14.53M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XINT Stock
  4. Financials Xintela AB